8th ReSViNET Conference
February 13 -16, 2024
Mumbai, India मुंबई, भारत
On 13-16 February 2024 the ReSViNET Foundation will host its 8th conference RSVVW’24 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions. Our mission is to increase awareness on the global burden of Respiratory Syncytial Virus (RSV), especially in low- and middle-income countries, therefore, we are proud to choose Mumbai, India as the RSVVW’24 conference destination. In India, RSV is responsible for a significant burden of respiratory disease among children under the age of five, which is why it is crucial to raise awareness and involve HCPs from these regions.

The aim of the conference is to learn and share knowledge on current research and to gather and connect the leading worldwide researchers, scientists, academic scientists, industry researchers, scholars, decision makers and other stakeholders in the RSV field.

A topical program is developed by the Scientific Advisory Board and session chairs which will be focused on the latest aspects of RSV prevention and treatment development. We expect attendees from all continents and anticipate an exciting scientific event that will expand our knowledge of RSV and disseminate new findings in preventive and therapeutic development.

We are delighted to see you again and thank you for joining us here in Mumbai!

Best wishes,

Also on behalf of the Organising Committee,

Louis Bont & Leyla Kragten-Tabatabaie

Namaste! !!
मुंबई में आपका स्वागत है !!
हम आप सभी से मिलने के लिए उत्सुक हैं।

Welcome to Mumbai
We are pleased to meet you
SCIENTIFIC ADVISORY BOARD

Heather Zar
Red Cross Children's Hospital & University of Cape Town
South Africa

Joyce Nyiro
KEMRI-Wellcome Trust Research Program
Kenya

Barney Graham
Morehouse School of Medicine
United States

Peter Openshaw
Imperial College London
United Kingdom

Harish Nair
The University of Edinburgh
United Kingdom

Naveen Thacker
Deep Children Hospital and Research Centre, Gandhidham
India

Padmini Srikantiah
Bill & Melinda Gates Foundation
United States

Mauricio Caballero
Fundación INFANT
Argentina

Ruth Karron
Johns Hopkins Bloomberg School of Public Health
United States
MUMBAI, INDIA

GEOGRAPHIC LOCATION
Mumbai (formerly called Bombay) is a densely populated city on India's west coast, capital of Maharashtra state. Located partly on Mumbai Island, it is flanked by Mumbai Harbour and the Arabian Sea.

WEATHER IN FEBRUARY
During the day, it's usually sunny with an average temperature of 30°C (86°F). At dusk, the temperature starts dropping to around 20°C (68°F).

TIME
Mumbai is in the Indian Standard Time (IST).

LANGUAGE
Marathi is the most common spoken language in Mumbai, however, English is widely used by all of those who work within the tourist industry, and tourists who only speak English will not encounter any language barriers during the duration of their holiday. All transport hubs have English as their second language and this includes railway, the metro and the airport. While dining out, most restaurants and cafes will be able to provide an English menu.
### Day 1: RSVVW’24 Pre-Conference Symposia  
**Tuesday, 13-Feb-2024**

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>10:30</td>
<td><strong>Symposium 1:</strong> A New Epoch in the Fight Against an Old Foe Threatening all Infants</td>
</tr>
<tr>
<td>10:30</td>
<td>10:45</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>10:45</td>
<td>12:15</td>
<td><strong>Symposium 2:</strong> The Gift of RSV Maternal Antibody: Protection from Birth</td>
</tr>
<tr>
<td>12:15</td>
<td>12:30</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>12:30</td>
<td>14:00</td>
<td><strong>Symposium 3:</strong> The A to Z of RSV</td>
</tr>
<tr>
<td>14:00</td>
<td>14:30</td>
<td><strong>Lunch Break</strong></td>
</tr>
<tr>
<td>14:30</td>
<td>16:00</td>
<td><strong>Symposium 4:</strong> RSV in Toddlers: Unmasking the Burden Beyond the First Year &amp; Exploring Protection</td>
</tr>
<tr>
<td>16:00</td>
<td>16:15</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>16:15</td>
<td>17:45</td>
<td><strong>Symposium 5:</strong> Respiratory Syncytial Virus (RSV) Non-Promotional Symposium: “Analysing the RSV Prevention Landscape Through Artificial Intelligence: Where Has 60 Years of Research Gotten Us?”</td>
</tr>
<tr>
<td>17:45</td>
<td>18:00</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>18:00</td>
<td>19:30</td>
<td><strong>Symposium 6:</strong> Not Just for Children: Recognizing the Impact of RSV on Older Adults</td>
</tr>
</tbody>
</table>

---

**A detailed program is outlined at the end of the Scientific Program.**

---

### Day 2: RSVVW’24  
**Wednesday, 14-Feb-2024**

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>10:10</td>
<td><strong>Conference Opening</strong></td>
<td>Marriott Grand Ballroom</td>
</tr>
<tr>
<td>10:10</td>
<td>10:20</td>
<td>Opening Remarks by the Conference Chairs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Louis Bont</strong> (Chairman, ReSViNET Foundation; Wilhelmina Children’s Hospital – Utrecht, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Leyla Kragten</strong> (Board of Directors, ReSViNET Foundation; Julius Clinical – Zeist, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>11:00</td>
<td>Keynote Lecture: Lessons Learned from Animals in Infectious Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Ab Osterhaus</strong> (Director of the Center of Infection Medicine &amp; Zoonosis Research &amp; Guest-Professor at the University of Veterinary Medicine Hannover – Hannover, Germany)</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>11:20</td>
<td><strong>Morning Break</strong></td>
<td>Pre-Function Area</td>
</tr>
</tbody>
</table>
**Day 2: RSVVW’24 (cont.)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Session 1: Global Impact of RSV</strong></td>
<td></td>
<td>Marriott Grand Ballroom</td>
</tr>
</tbody>
</table>
| 11:20 - 11:30 | Session Introduction by Session Chairs  
Harish Nair (University of Edinburgh – Edinburgh, UK)  
Varsha Potdar (ICMR National Institute of Virology – Pune, India) | Marriott Grand Ballroom |
| 11:30 - 11:45 | RSV Burden in India  
Ashish Satav (MAHAN Trust – Dharani, Amaravati, India) | Marriott Grand Ballroom |
| 11:45 - 12:00 | Global Burden of RSV Disease by Age & Severity in Children  
You Li (Nanjing Medical University - Nanjing, China) | Marriott Grand Ballroom |
| 12:00 - 12:15 | Burden of RSV Disease in Older Adults  
Edward Walsh (University of Rochester Medical Center – Rochester, NY, USA) | Marriott Grand Ballroom |
| 12:15 - 12:30 | RSV Transmission – Will Preventive Strategies in Infants or Adults Reduce Transmission?  
Patrick Munywoki (US Centers for Disease Control & Prevention (CDC) – Nairobi, Kenya) | Marriott Grand Ballroom |
| 12:30 - 12:50 | Panel Discussion with Speakers & Chairs  
Harish Nair, Varsha Potdar, You Li, Edward Walsh, Patrick Munywoki | Marriott Grand Ballroom |
| 12:50 - 14:20 | Lunch | Patio Area |
| **Session 2: Patient Involvement and Ethics** |                                                                                  | Marriott Grand Ballroom |
| 14:20 - 14:30 | Session Introduction by Session Chairs  
Barney Graham (Morehouse School of Medicine – Atlanta, GA, USA)  
Anant Bhan (Yenepoya Medical College & Centre for Ethics, Yenepoya University – Mangalore, India) | Marriott Grand Ballroom |
| 14:30 - 14:40 | Patient Involvement & Ethics  
Anant Bhan (Yenepoya Medical College & Centre for Ethics, Yenepoya University – Mangalore, India) | Marriott Grand Ballroom |
| 14:40 - 14:50 | Ethics in Development of RSV Interventions  
Natalie Mazur (Wilhelmina Children’s Hospital – Utrecht, The Netherlands) | Marriott Grand Ballroom |
| 14:50 - 15:00 | Introduction: Parent of a Child with RSV  
Rachael Thomas (ReSViNET Patient Network Representative – East Sussex, United Kingdom) | Marriott Grand Ballroom |
| 15:00 - 15:40 | Panel Discussion: Parents’ & Experts’ views with:  
Barney Graham, Anant Bhan, Natalie Mazur, Rachael Thomas  
Lisa van Wissen (ReSViNET Patient Network Representative – The Netherlands) | Marriott Grand Ballroom |
| 15:40 - 16:45 | Poster Break (Category: Clinical Studies) | Junior Ballroom |
| **Young Researchers’ Tournament** |                                                                                  | Marriott Grand Ballroom |
| 16:45 - 16:50 | Session Introduction by Session Chairs  
Paolo Manzoni (University of Turin School of Medicine – Turin, Italy)  
Ashley Murray (Baylor College of Medicine – Houston, Texas, USA) | Marriott Grand Ballroom |
| 16:50 - 17:05 | Single-Cell Sequencing Analysis of RSV Infected Pediatric & Adult Human Nose Organoids Reveals Age Differences, Proliferative Diversity, Identifies Novel Tropism, & Antiviral Response  
Anubama Rajan (Sri Ramachandra Institute of Higher Education & Research – India) | Marriott Grand Ballroom |
| 17:05 - 17:20 | RSV Neutralizing Antibodies in Dried Blood  
Jonne Terstappen (Wilhelmina Children’s Hospital & University Medical Center Utrecht – Utrecht, The Netherlands) | Marriott Grand Ballroom |
| 17:20 - 17:35 | Age-Dependent Constitutive Expression & Antiviral Activity of Interferon Epsilon Against RSV in Airway Epithelium  
Mary McCabe (Queen’s University Belfast – Belfast, Ireland, United Kingdom) | Marriott Grand Ballroom |
| 17:35 - 17:50 | In-Silico Design of a Multi-Epitope Chimeric Vaccine Candidate Against RSV Disease  
Tangan Yannick (University of Buea – Buea, Cameroon) | Marriott Grand Ballroom |
| 17:50 - 18:00 | Afternoon Break | Pre-Function Area |
| 18:00 - 19:00 | MASTER CLASS: How to Get Published  
Rick Grobbee (Julius Clinical – Utrecht, The Netherlands) | Marriott Grand Ballroom |
| 18:00 - 19:00 | MASTER CLASS: How to Bring Equity in Your Research  
Barney Graham (Morehouse School of Medicine – Atlanta, GA, USA) | Marriott Grand Ballroom |
| 19:00 - 22:00 | Welcome Reception | Pre-Function & Patio Area |
| 20:00 - 20:30 | Inspirational Speaker: Dr Pawan Agarwal (Mumbai Dabbawallas – Mumbai, India) | Marriott Grand Ballroom |
### Session 3: RSV Clinical Interventions and Their Global Use

**Marriott Grand Ballroom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td><strong>Session Introduction by Session Chairs</strong>&lt;br&gt;Ruth Karron (Johns Hopkins Bloomberg School of Public Health – Baltimore, MD, USA)&lt;br&gt;Jacob John (Christian Medical College (CMC) Vellore – Vellore, India)</td>
</tr>
<tr>
<td>9:45</td>
<td>Live-Attenuated Respiratory Syncytial Virus Vaccine for the Prevention of RSV Disease is Safe &amp; Immunogenic in 6- to 18-Month-Old Children&lt;br&gt;Olubukola Idoko (Sanofi – Lyon, France)</td>
</tr>
<tr>
<td>10:00</td>
<td>Safety &amp; Immunogenicity of a RSV &amp; HMPV Bivalent Virus-like Particle Protein Subunit Vaccines in Older Adults&lt;br&gt;Niranjan Kanesa-Hasan (Icosavax, Inc. – Seattle, WA, USA)</td>
</tr>
<tr>
<td>10:20</td>
<td>A Pharmacokinetic &amp; Safety Study of Sisunatovir, a Potent RSV Fusion Inhibitor with Demonstrated Antiviral Activity, in Hospitalized Infants with RSV Lower Respiratory Tract Infection&lt;br&gt;Sima Toussi (Pfizer Anti-Infectives Clinical Research Unit – Pearl River, NY, USA)</td>
</tr>
<tr>
<td>10:35</td>
<td>A Phase 1b/2a Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, &amp; Pharmacokinetics of an RSV-Neutralizing Antibody, Clesrevimab, in Pre-Term &amp; Full-Term Infants&lt;br&gt;Anushua Sinha (Merck &amp; Co., Inc. – Rahway, NJ, USA)</td>
</tr>
<tr>
<td>10:50</td>
<td><strong>Poster Break</strong> (Category: Evolution &amp; Epidemiology)</td>
</tr>
<tr>
<td>12:00</td>
<td>Efficacy &amp; Safety of mRNS-1345, an RSV Vaccine, in Older Adults through ≥6 Months of Follow-Up &amp; Evaluation of Correlate of Protection Against RSV&lt;br&gt;Jaya Goswami &amp; Lingyi Zheng (Moderna, Inc. – Cambridge, MA, USA)</td>
</tr>
<tr>
<td>12:15</td>
<td>Vaccine Efficacy &amp; Waning Values from the Adjuvanted RSV Pre-Fusion F Protein-Based Vaccine Clinical Trial&lt;br&gt;Daniel Molnar (GSK – Wavre, Belgium)</td>
</tr>
<tr>
<td>12:30</td>
<td>Protection Against Infant Illness with a Bivalent RSVpreF Vaccine in Pregnancy&lt;br&gt;Iona Munjal (Pfizer Vaccines – Pearl River, NY, USA)</td>
</tr>
<tr>
<td>12:50</td>
<td>WHO RSV Roadshow Announcement&lt;br&gt;Daniel Felkin (Initiative for Vaccine Research- Immunizations, Vaccines &amp; Biologicals, World Health Organization (WHO) - Geneva, Switzerland)</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Lunch</strong></td>
</tr>
</tbody>
</table>

**Session 3: RSV Clinical Interventions and Their Global Use (cont.)**

**Marriott Grand Ballroom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Efficacy &amp; Safety of mRNS-1345, an RSV Vaccine, in Older Adults through ≥6 Months of Follow-Up &amp; Evaluation of Correlate of Protection Against RSV&lt;br&gt;Jaya Goswami &amp; Lingyi Zheng (Moderna, Inc. – Cambridge, MA, USA)</td>
</tr>
<tr>
<td>12:15</td>
<td>Vaccine Efficacy &amp; Waning Values from the Adjuvanted RSV Pre-Fusion F Protein-Based Vaccine Clinical Trial&lt;br&gt;Daniel Molnar (GSK – Wavre, Belgium)</td>
</tr>
<tr>
<td>12:30</td>
<td>Protection Against Infant Illness with a Bivalent RSVpreF Vaccine in Pregnancy&lt;br&gt;Iona Munjal (Pfizer Vaccines – Pearl River, NY, USA)</td>
</tr>
<tr>
<td>12:50</td>
<td>WHO RSV Roadshow Announcement&lt;br&gt;Daniel Felkin (Initiative for Vaccine Research- Immunizations, Vaccines &amp; Biologicals, World Health Organization (WHO) - Geneva, Switzerland)</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Lunch</strong></td>
</tr>
</tbody>
</table>

### Session 4: Implementation of RSV Interventions

**Marriott Grand Ballroom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:40</td>
<td><strong>Session Introduction by Session Chairs</strong>&lt;br&gt;Joyce Nyiro (KEMRI-Wellcome Trust Research Program – Kiifi, Kenya)&lt;br&gt;Jessica Fleming (PATH Center for Vaccine Innovation &amp; Access – Seattle, WA, USA)</td>
</tr>
<tr>
<td>14:45</td>
<td>Delivery Mechanisms of mAbs &amp; Maternal Vaccines Through Healthcare System&lt;br&gt;Rose Jalang’o (National Vaccines &amp; Immunization Program, Ministry of Health – Nairobi, Kenya)</td>
</tr>
<tr>
<td>15:00</td>
<td>Health Facilities Maternal Immunization Readiness Assessment Tool&lt;br&gt;Rosemary Njogu (Senior Program Lead- Immunization &amp; RISE -USAID projects, Jhpiego – Nairobi, Kenya)</td>
</tr>
<tr>
<td>15:15</td>
<td>Rolling Out a Vaccine in India&lt;br&gt;Pradeep Haldar (Former Advisor (RCH) Govt. of India &amp; Independent Consultant - India)</td>
</tr>
<tr>
<td>15:30</td>
<td>Q&amp;A &amp; Panel Discussion with all Chairs &amp; Speakers&lt;br&gt;Joyce Nyiro, Jessica Fleming, Rose Jalang’o, Rosemary Njogu, Pradeep Haldar</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>Poster Break</strong> (Category: Vaccines, Therapies &amp; Treatments)</td>
</tr>
</tbody>
</table>
### Day 3: RSVVW’24 (cont.)

**Thursday, 15-Feb-2024**

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Session 5: RSV Co-Infection and Long-Term Impact</strong></td>
<td></td>
<td>Marriott Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>16:50</td>
<td><strong>Session Introduction by Session Chairs</strong>&lt;br&gt;Heather Zar (School of Child &amp; Adolescent Health at the University of Cape Town (UCT) – Cape Town, South Africa)&lt;br&gt;Renato Stein (Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) – Porto Alegre, Brazil)</td>
<td></td>
</tr>
<tr>
<td>16:50</td>
<td>17:05</td>
<td>The Microbiota of the Respiratory Tract &amp; Its Role in RSV &amp; Other Viral Diseases&lt;br&gt;Debby Bogaert (Chair of Paediatric Medicine, University of Edinburgh – Edinburg, UK)</td>
<td></td>
</tr>
<tr>
<td>17:05</td>
<td>17:20</td>
<td>RSV-Pneumococcal Interactions – Will RSV Prevention Have a Bigger Impact on LRTI Epidemiology?&lt;br&gt;Ron Dagan (Distinguished Professor of Paediatrics &amp; Infectious Diseases, The Shraga Segal Dept. of Microbiology, Immunology &amp; Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev Beer-Sheva, Israel)</td>
<td></td>
</tr>
<tr>
<td>17:20</td>
<td>17:35</td>
<td>Early-Life Viral Infections &amp; Impact on Wheezing Phenotypes&lt;br&gt;Renato Stein (Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) – Porto Alegre, Brazil)</td>
<td></td>
</tr>
</tbody>
</table>
| 17:35  | 17:50 | Q&A & Panel Discussion with all Chairs & Speakers<br>Heather Zar, Renato Stein, Debby Bogaert, Ron Dagan | Lawn Area
| 17:50  | 19:00 | Free time | |
| 19:00  | 22:00 | Optional Networking Dinner | *Please note, attendance for dinner is only possible if registered for the Networking Event |

### Day 4: RSVVW’24

**Friday, 16-Feb-2024**

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Session 6: Vaccine Immunology</strong></td>
<td></td>
<td>Marriott Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>10:10</td>
<td><strong>Opening Remarks by Conference Chairs</strong></td>
<td>Marriott Grand Ballroom</td>
</tr>
<tr>
<td>10:10</td>
<td>10:20</td>
<td><strong>Session Introduction by Session Chairs</strong>&lt;br&gt;Tony Piedra (Baylor College of Medicine – Houston, TX, USA)&lt;br&gt;Ursula Buchholz (National Institute of Allergy &amp; Infectious Diseases (NIAID), national Institutes of Health (NIH) – Bethesda, MD, USA)</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>10:40</td>
<td>Biomarkers of Childhood Respiratory Disease&lt;br&gt;Charles Sande (Centre for Tropical Medicine &amp; Global Health, University of Oxford – Oxford, UK)</td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>11:00</td>
<td>Life-Attenuated Vaccines&lt;br&gt;Ursula Buchholz (National Institute of Allergy &amp; Infectious Diseases (NIAID), national Institutes of Health (NIH) – Bethesda, MD, USA)</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>11:20</td>
<td>Protecting Infants (6-12 months) Against RSV&lt;br&gt;Barney Graham (Morehouse School of Medicine – Atlanta, GA, USA)</td>
<td>Junior Ballroom</td>
</tr>
<tr>
<td>11:20</td>
<td>12:20</td>
<td><strong>Poster Break (Category: Virology &amp; Immunology)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Session 7: LMIC Health Economics and Policy</strong></td>
<td></td>
<td>Marriott Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>12:30</td>
<td><strong>Session Introduction by Session Chairs</strong>&lt;br&gt;Padmini Srikantiah (Deputy Director, Bill &amp; Melinda Gates Foundation – Seattle, WA, USA)&lt;br&gt;Neele Rave (University Medical Center Utrecht – Utrecht, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>12:45</td>
<td>Moving the Agenda for RSV Prevention Forward – WHO Perspective&lt;br&gt;Daniel Feikin (Initiative for Vaccine Research- Immunizations, Vaccines &amp; Biologicals, World Health Organization (WHO) - Geneva, Switzerland)</td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td>13:00</td>
<td>UNIVAC Model for RSV Interventions CEA&lt;br&gt;Andrew Clark (London School of Hygiene &amp; Tropical Medicine (LSHTM) – London, UK)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>13:15</td>
<td>Introducing RSV Prevention Interventions in Infants in LMICs – Cost-Effectiveness &amp; Policy Considerations&lt;br&gt;Cheryl Cohen (National Institute for Communicable Diseases (NICD) – Johannesburg, South Africa)</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>13:30</td>
<td>Q&amp;A &amp; Panel Discussion with all Chairs &amp; Speakers&lt;br&gt;Padmini Srikantiah, Neele Rave, Daniel Feikin, Andrew Clark, Cheryl Cohen</td>
<td>Patio Area</td>
</tr>
<tr>
<td>13:30</td>
<td>15:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>From</td>
<td>Until</td>
<td>Title &amp; Speakers</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>15:00</td>
<td>15:10</td>
<td>Session Introduction by Session Chairs</td>
<td>Marriott Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Naveen Thacker</strong> (President of The International Pediatric Association (IPA) – Marengo, IL, USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Shobha Broor</strong> (SGT University – Gurgaon, India)</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>15:25</td>
<td>An Overview of Global Challenges</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Naveen Thacker</strong> (President of the IPA – USA &amp; Child Health Foundation – India)</td>
<td></td>
</tr>
<tr>
<td>15:25</td>
<td>15:40</td>
<td>Implementing Strategies to Prevent RSV-LRTI in Infants in LMICs – Addressing Global Vaccine Inequity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Anuradha Gupta</strong> (President of Global Immunization, Sabin Vaccine Institute – Washington DC, USA)</td>
<td></td>
</tr>
<tr>
<td>15:40</td>
<td>15:55</td>
<td>Optimal Strategies for Preventing RSV Disease in Infants in LMICs – Seasonal vs. Year Round Immunisation, mAb vs. Maternal Immunisation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sir Andrew Pollard</strong> (Director of the Oxford Vaccine Group – Oxford, UK)</td>
<td></td>
</tr>
<tr>
<td>15:55</td>
<td>16:10</td>
<td>Assessing Vaccines for Decision Making – GAVI’s Vaccine Investment Strategy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Marta Tufet</strong> (GAVI, The Vaccine Alliance – Geneva, Switzerland)</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>16:30</td>
<td>Q&amp;A and Panel Discussion with all Chairs &amp; Speakers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Naveen Thacker, Shobha Broor, Sir Andrew Pollard, Marta Tufet</strong></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>16:40</td>
<td>Announcement YRT Winner</td>
<td>Marriott Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Paolo Manzoni</strong> (University of Torino School of Medicine – Turin, Italy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Ashley Murray</strong> (Baylor College of Medicine – Houston, Texas, USA)</td>
<td></td>
</tr>
<tr>
<td>16:40</td>
<td>17:00</td>
<td>Closing Remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Louis Bont</strong> (Chairman, ReSViNET Foundation; Wilhelmina Children’s Hospital – Utrecht, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Leyla Kragten</strong> (Board of Directors, ReSViNET Foundation; Julius Clinical – Zeist, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>18:00</td>
<td>Refreshments</td>
<td>Pre-Function Area &amp; Junior Ballroom</td>
</tr>
<tr>
<td>Time</td>
<td>From</td>
<td>Until</td>
<td>Title &amp; Speakers</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-------</td>
<td>------------------</td>
</tr>
<tr>
<td>9:00</td>
<td>9:05</td>
<td></td>
<td>Welcome &amp; Introductions</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Prof. Federico Martínón- Torres, MD</strong> (Head of Pediatrics, Hospital Clínico, Universitario de Santiago, Professor of Pediatrics, University of Santiago de Compostela - Santiago, Spain)</td>
</tr>
<tr>
<td>9:05</td>
<td>9:30</td>
<td></td>
<td>Protecting Infants Against RSV Disease in New Epoch</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Asunción Mejías, MD, PhD, MsCS</strong> (Professor of Pediatrics, Member, St Jude Faculty, Department of Infectious Diseases, St Jude Children’s Research Hospital – Tennessee, USA)</td>
</tr>
<tr>
<td>9:30</td>
<td>9:50</td>
<td></td>
<td>Implementation of Long-Acting mAb for Protection Against RSV LRTD in the Broad Infant Population</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Prof. Federico Martínón- Torres, MD</strong> (Head of Pediatrics, Hospital Clínico, Universitario de Santiago, Professor of Pediatrics, University of Santiago de Compostela - Santiago, Spain)</td>
</tr>
<tr>
<td>9:50</td>
<td>10:15</td>
<td></td>
<td>Molecular Evolution of RSV and Sustainability of RSV Disease Prevention</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Joseph Domachowske, MD</strong> (Professor of Pediatrics, Professor of Microbiology and Immunology, Pediatric Infectious Diseases, State University of New York – New York – U.S.A)</td>
</tr>
<tr>
<td>10:15</td>
<td>10:30</td>
<td></td>
<td>Discussion Wrap Up / Q&amp;A Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>All Speakers</td>
</tr>
<tr>
<td>10:30</td>
<td>10:45</td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>10:45</td>
<td>10:50</td>
<td></td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Louis Bont, MD, PhD</strong> (Pediatric Infectious Diseases Specialist, Chairman, ReSViNET Foundation; Head of the dept of Pediatrics, Wilhelmina Children’s Hospital &amp; University Medical Center Utrecht – Utrecht, The Netherlands)</td>
</tr>
<tr>
<td>10:50</td>
<td>11:15</td>
<td></td>
<td>Historical Review of Maternal Immunization</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Janet A. Englund, MD</strong> (Professor of Pediatrics, University of Washington, Division of Pediatric Infectious Disease, Seattle Children’s Hospital – Seattle, WA, USA)</td>
</tr>
<tr>
<td>11:15</td>
<td>11:35</td>
<td></td>
<td>Maternal immunization as a key strategy for RSV prevention in infants</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Asunción Mejías, MD, PhD, MsCS</strong> (Professor of Pediatrics, Member, St Jude Faculty, Department of Infectious Diseases, St Jude Children’s Research Hospital – Memphis, TN, USA)</td>
</tr>
<tr>
<td>11:35</td>
<td>11:55</td>
<td></td>
<td>Maternal RSV antibodies: transplacental transfer, persistence, and duration of protection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Jessica Atwell, PhD, MPH</strong> (Global Scientific Affairs and Epidemiology Lead, RSV Maternal and Pediatric Vaccine, Global Respiratory Vaccines and Antivirals, Pfizer, Inc. – Flagstaff, AZ, USA)</td>
</tr>
<tr>
<td>11:55</td>
<td>12:15</td>
<td></td>
<td>Panel Discussion / Q&amp;A Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>All Speakers</td>
</tr>
<tr>
<td>12:15</td>
<td>12:30</td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>From</td>
<td>Until</td>
<td>Title &amp; Speakers</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
</tbody>
</table>
| 12:30  | 12:35   | **Welcome & Introduction**  
**Dr Paolo Manzoni, MD, PhD** (Department of Public Health and Paediatric Sciences, University of Torino School of Medicine, Turin, Italy; Division of Paediatrics and Neonatology, Degli Infermi Hospital - Ponderano, Italy) | Marriott Grand Ballroom              |
| 12:35  | 12:50   | **Global RSV Burden**  
**Dr Renato T. Stein, MD, MPH, PhD** (Centro Infant, Department of Pediatrics School of Medicine Pontificia Universidade Católica do Rio Grande do Sul (PUCRS) - Porto Alegre, RS, Brazil) | Marriott Grand Ballroom              |
| 12:50  | 13:05   | **RSV in NICU**  
**Dr Suman Rao P.N., MD, DM** (Prof. & Head, Department of Neonatology, ICMR Collaborating Centre of Excellence, St. John’s Medical College Hospital - Bangalore, India) | Marriott Grand Ballroom              |
| 13:05  | 13:20   | **Risk Stratification for At-Risk & High-Risk Newborns Beyond Prematurity: Big Problems, Big Solutions**  
**Dr Paolo Manzoni, MD, PhD** (Department of Public Health and Paediatric Sciences, University of Torino School of Medicine, Turin, Italy; Division of Paediatrics and Neonatology, Degli Infermi Hospital - Ponderano, Italy) | Marriott Grand Ballroom              |
| 13:20  | 13:55   | **Panel Discussion**  
Moderated by **Dr Renato T. Stein, MD, MPH, PhD**  
Panellists:  
**Dr Paolo Manzoni, MD, PhD**  
**Dr Suman Rao PN, MD, DM**  
**Dr Satish Saluja, MD** (Senior Consultant, Neonatology, Sir Ganga Ram Hospital - New Delhi, India) | Marriott Grand Ballroom              |
| 13:55  | 14:00   | **Wrap Up & Closing**  
**Dr Paolo Manzoni, MD, PhD** | Marriott Grand Ballroom              |
| 14:00  | 14:30   | **Lunch Break** | Patio Area                          |
| 14:30  | 14:35   | **Welcome & Introductions**  
**Asunción Mejías, MD, PhD, MsCS** (Professor of Pediatrics, Member, St Jude Faculty, Department of Infectious Diseases, St Jude Children’s Research Hospital – Tennessee, U.S.A) | Marriott Grand Ballroom              |
| 14:35  | 15:15   | **Beyond the First Year: the Ongoing Challenge of RSV**  
Chaired by **Prof Asunción Mejías**  
Panellists:  
**Prof Marta Nunes** (Université Claude Bernard Lyon 1 – Lyon, France)  
**Prof Caterina Rizzo** (Università di Pisa – Pisa, Italy)  
**Dr Felicity Liew** (Imperial College London - London, United Kingdom) | Marriott Grand Ballroom              |
| 15:15  | 15:50   | **Mucosal Immunity: Utilising the Frontline Defence to Protect Against RSV**  
Chaired by **Prof Asunción Mejías**  
Panellists:  
**Prof Marta Nunes, Prof Caterina Rizzo, Dr Felicity Liew** | Marriott Grand Ballroom              |
| 15:50  | 16:00   | **Audience Questions & Chair’s Summary**  
**Prof Asunción Mejías, Prof Marta Nunes, Prof Caterina Rizzo, Dr Felicity Liew** | Marriott Grand Ballroom              |
| 16:00  | 16:15   | **Break** | Pre-Function Area                |
### Day 1: RSVVW’24 Pre-Conference Symposia (cont.)

**Tuesday, 13-Feb-2024**

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>16:25</td>
<td>Welcome &amp; Introductions</td>
</tr>
<tr>
<td>16:25</td>
<td>16:45</td>
<td>What Does the Current Landscape of RSV Look Like &amp; What Did it Take for Us to Get Here?</td>
</tr>
<tr>
<td>16:45</td>
<td>17:05</td>
<td>How Does Data Reflect the Patient Journey?</td>
</tr>
<tr>
<td>17:05</td>
<td>17:25</td>
<td>Adult Immunization in India &amp; What it Means for RSV</td>
</tr>
<tr>
<td>17:25</td>
<td>17:35</td>
<td>Rapid Q&amp;A Session</td>
</tr>
<tr>
<td>17:35</td>
<td>17:45</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
<tr>
<td>17:45</td>
<td>18:00</td>
<td>Break</td>
</tr>
</tbody>
</table>

#### Respiratory Syncytial Virus (RSV) Non-Promotional Symposium: “Analysing the RSV Prevention Landscape Through Artificial Intelligence: Where Has 60 Years of Research Gotten Us?”

**Sponsored by GSK**

Marriott Grand Ballroom

- **Dr Edward Walsh** (Professor Department of Medicine, University of Rochester - New York, USA)
- **Prof Federico Martinón-Torres** (Head of Pediatrics & Director of Translational Pediatrics & Infectious Diseases, Santiago Clinic Hospital – Santiago, Spain)
- **Dr V Ramasubramanian** (Infectious Disease Specialist, Apollo Hospitals - Chennai, India)
- **Catherine Weil-Olivier, MD** (Honorary Professor of Pediatrics, University Paris-Cité, France)
- **Paolo Manzoni, MD, PhD** (Professor of Pediatrics and Neonatology, University of Torino School of Medicine, Turin, Italy)
- **Harish Nair, FRSE, FRCPE, FFPH** (Chair of Paediatric Infectious Diseases and Global Health, Co-Director of Centre for Global Health, University of Edinburgh – Edinburgh, UK)
- **Dr Edward Walsh** (Professor Department of Medicine, University of Rochester – Rochester, NY, USA)

### Not Just for Children: Recognizing the Impact of RSV on Older Adults

**Sponsored by Pfizer**

Marriott Grand Ballroom

<table>
<thead>
<tr>
<th>From</th>
<th>Until</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>18:05</td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td>18:05</td>
<td>18:20</td>
<td>RSV Infection in the Context of Other Respiratory Viruses</td>
</tr>
<tr>
<td>18:20</td>
<td>18:35</td>
<td>Key Risk Factors for Severe RSV Disease</td>
</tr>
<tr>
<td>18:35</td>
<td>18:50</td>
<td>The Hidden Burden of RSV in Adults</td>
</tr>
<tr>
<td>18:50</td>
<td>19:05</td>
<td>Sequelae of RSV Infection in Older Adults</td>
</tr>
<tr>
<td>19:05</td>
<td>19:30</td>
<td>Panel Discussion / Q&amp;A Session</td>
</tr>
</tbody>
</table>

- **Dr Edward Walsh** (Professor Department of Medicine, University of Rochester – Rochester, NY, USA)
THE CONFERENCE SPACE

The conference venue, JW Marriott Sahar Mumbai Hotel, is ideally located in Andheri East, close to Mumbai’s international and domestic airports. With spacious meeting rooms, a comfortable and large plenary hall, serene garden, and excellent catering services, the JW Marriott Sahar Mumbai Hotel is an excellent venue for our conference.

THE JW MARRIOTT MUMBAI SAHAR HOTEL

Unparalleled world-class service await you at JW Marriott Mumbai Sahar in India. The hotel accommodations feature 588 spacious rooms with pillowtop beds, marble bathrooms and high-speed Wi-Fi, as well as generous work desks and 24-hour room service. During your free time, you can relax at the spa and fitness center or the poolside lounge area with cabanas, perfect for soaking up the warm sun.

- Located in Andheri East, close to Mumbai's international and domestic airports
- 588 rooms and suites
- Conference area, Fitness Center, Restaurant, Outdoor Pool and Spa

ADDRESS

JW Marriott Mumbai Sahar Hotel
IA Project Road, Chhatrapati Shivaji International Airport, Andheri Mumbai, India 400099

WEBSITE

www.jwmarriottmumbai.com
CONFERENCE VENUE

JW MARRIOTT MUMBAI
SAHAR HOTEL

VENUE MAP

- Entrance Conference Area
- Registration
- Faculty Preview Room
- Refreshments
- Masterclasses
- Meeting Rooms
- Lunch/Dinner Buffet
- Plenary Hall
- Exhibition Area
- Poster Area
EVENING PROGRAM

The evening program is an opportunity for our participants to experience the charm of Mumbai and the taste of Indian cuisine.

RECEPTION

To welcome you to our 8th ReSViNET Conference, we will be hosting a reception on the second evening February 14, 2024. The location of the reception will be outside in the garden of MARRIOTT SAHAR hotel with a complimentary welcome drink and delicious finger food.

DINNER

On the third evening of the program we will be hosting a dinner at the MARRIOTT SAHAR in the garden of the hotel.
ReSViNET’s journey towards global conferences had its beginnings back in 2015 which started with small scale meetings. We are extremely proud to see the journey from small-scale expert meetings to today’s conferences of over 300 attendees that took place in different countries, including the Netherlands, Spain and Ghana.
Reduce the Global Burden of RSV Infection

The Foundation

The ReSViNET Foundation is the international leading non-profit organisation committed to reducing the global burdens of RSV infection.

Network

A global network of experts in the field of RSV infections, combining the knowledge and capacity required to enhance development of novel RSV therapeutics.

Patient Network

A network of everyone who is effected by RSV. We are committed to raise awareness about RSV, representing patient perspective in medical research. We serve as a source of peer support and knowledge exchange.

OUR MISSION

To connect global expertise and leadership in order to decrease the global burden of RSV infection.

OUR VISION

To support performance of high quality research, to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic interventions.

OUR GOALS

Advocate and create awareness for the RSV disease. Combine knowledge and capacity required to enhance development of novel RSV therapeutics.
Combining expertise and leadership to decrease the global burden of RSV infection

ORGANISING COMMITTEE

Louis Bont
ReSViNET Chairman
The Netherlands

Nina Omerovic
ReSViNET Associate
The Netherlands

Leyla Kragten
ReSViNET Board of Directors
The Netherlands

Marjon Dofferhoff
ReSViNET Head of MarCom
The Netherlands

Roxie van Lieshout
ReSViNET Head of Scientific
The Netherlands

Sophie Mazur
ReSViNET Manager
The Netherlands

STAY UPDATED!

www.resvinet.org

ReSViNET | Respiratory Syncytial Virus (RSV) Foundation

@ReSViNET

Sign up for our mailinglist: info@resvinet.org
ACKNOWLEDGEMENTS

RSVVW’24 IS SPONSORED BY: